Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Supernus Pharmaceuticals Inc. | Dalzanemdor (SAGE-718) - (LIGHTWAVE) | Mild cognitive impairment and mild dementia due to AD | Phase 2 | Data Released | Oral | Neurology |
| Supernus Pharmaceuticals Inc. | Dalzanemdor (SAGE-718) - (PRECEDENT) | Mild cognitive impairment (MCI) | Phase 2 | Trial Discontinued | oral | Neurology |
| Supernus Pharmaceuticals Inc. | SAGE-718 - (SURVEYOR) | Huntington's disease | Phase 2 | Data Released | oral | Neurology |
| Supernus Pharmaceuticals Inc. | SPN-817 | Treatment-resisted seizures | Phase 2 | Data Released | Oral | Neurology |
| Supernus Pharmaceuticals Inc. | SAGE-718 (718-CNA-201) - (LUMINARY) | Alzheimer’s disease (AD) cognitive dysfunction and mild dementia | Phase 2a | Ongoing | Oral | Neurology |
| Sutro Biopharma Inc. | Luvelta - (REFRαME-O1) | Platinum-resistant ovarian cancer (PROC) | Phase 2/3 | Trial Discontinued | Intravenous | Oncology |
| Sutro Biopharma Inc. | Luveltamab tazevibulin (luvelta) - (REFRαME-L1) | Non-Small Cell Lung Cancer | Phase 2 | Trial Discontinued | Intravenous | Oncology |
| Syndax Pharmaceuticals Inc. | E2112 | HR+, HER2- breast cancer | Phase 3 | Trial Discontinued | Oral | Oncology |
